Rondevaldova Johana, Hummelova Jana, Tauchen Jan, Kokoska Ladislav
1 Department of Crop Sciences and Agroforestry, Faculty of Tropical AgriSciences, Czech University of Life Sciences Prague , Prague, Czech Republic .
2 Department of Quality of Agricultural Products, Faculty of Agrobiology, Food and Natural Resources, Czech University of Life Sciences Prague , Prague, Czech Republic .
Microb Drug Resist. 2018 Jan/Feb;24(1):24-29. doi: 10.1089/mdr.2017.0033. Epub 2017 Jun 1.
Staphylococcal infections are often hard to treat due to increasing resistance, especially to β-lactams. Previous studies described the synergy between common antibiotics and isoflavonoids; however, little is yet known about the combinatory effects of antibiotics with products of human isoflavone metabolism. In this study, demethyltexasin (DT), a human body metabolite of soybean isoflavones, was evaluated for its possible antistaphylococcal combinatory effect with amoxicillin and oxacillin. For comparison, common therapeutically used combination of amoxicillin/clavulanic acid was tested. DT showed strong synergistic interactions against most of Staphylococcus aureus strains when combined with amoxicillin (sum of fractional inhibitory concentrations [ΣFIC] 0.257-0.461) and oxacillin (ΣFIC 0.109-0.484). When oxacillin was combined with DT, resistance to this antibiotic was overcome in many cases. Moreover, antibiotic/DT combinations were effective mainly against methicillin-resistant S. aureus (MRSA); however, the commonly used drug amoxicillin/clavulanic acid was effective only against sensitive strains. Our results indicated DT as a compound able to act synergistically with β-lactams. In addition, some combinations are effective against MRSA and decrease staphylococcal resistance. To the best of our knowledge this is the first report of the antimicrobial synergistic effects of isoflavone human body metabolite with common antibiotics. DT seems to be a possible candidate for further research focused on antistaphylococcal drug development, especially against antibiotic-resistant strains.
由于耐药性不断增加，尤其是对β-内酰胺类药物的耐药性，葡萄球菌感染往往难以治疗。先前的研究描述了常见抗生素与异黄酮之间的协同作用；然而，关于抗生素与人体异黄酮代谢产物的联合作用，目前所知甚少。在本研究中，对大豆异黄酮的人体代谢产物去甲基柚木黄酮（DT）与阿莫西林和苯唑西林的抗葡萄球菌联合作用进行了评估。为作比较，测试了常用的阿莫西林/克拉维酸治疗组合。DT与阿莫西林联合使用时（部分抑菌浓度总和[ΣFIC]为0.257 - 0.461）以及与苯唑西林联合使用时（ΣFIC为0.109 - 0.484），对大多数金黄色葡萄球菌菌株显示出强烈的协同相互作用。当苯唑西林与DT联合使用时，在许多情况下克服了对这种抗生素的耐药性。此外，抗生素/DT组合主要对耐甲氧西林金黄色葡萄球菌（MRSA）有效；然而，常用药物阿莫西林/克拉维酸仅对敏感菌株有效。我们的结果表明DT是一种能够与β-内酰胺类药物协同作用的化合物。此外，一些组合对MRSA有效并降低葡萄球菌耐药性。据我们所知，这是关于异黄酮人体代谢产物与常见抗生素抗菌协同作用的首次报道。DT似乎是进一步开展抗葡萄球菌药物研发研究的一个可能候选物，特别是针对抗生素耐药菌株。
